Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series

20252 citationsJournal Articlegold Open Access

Authors

Within-class switching from a prior anti-CD20 mAb therapy to ublituximab is feasible and may improve outcomes in some people with MS.

Published in: Frontiers in Immunology

Volume 16, pp. 1527102-1527102

Field-Weighted Citation Impact: 2.70